CGRP makes a comeback as antibodies advance into Phase II trials.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
The calcitonin gene-related peptide receptor antagonist MK-8825 decreases spinal trigeminal activity during nitroglycerin infusion
The Journal of Headache and Pain Open Access 20 November 2013
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Rights and permissions
About this article
Cite this article
Dolgin, E. Antibody drugs set to revive flagging migraine target. Nat Rev Drug Discov 12, 249–250 (2013). https://doi.org/10.1038/nrd3991
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd3991
This article is cited by
-
The calcitonin gene-related peptide receptor antagonist MK-8825 decreases spinal trigeminal activity during nitroglycerin infusion
The Journal of Headache and Pain (2013)